Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia
نویسندگان
چکیده
منابع مشابه
What is treatment free remission in chronic myeloid leukemia?
Chronic myeloid leukemia (CML) has become a model for molecular targeted therapy [1]. It is characterized by a cytogenetic marker, the Philadelphia (Ph) chromosome and its molecular counterpart the BCRABL1 fusion gene. This leukemia-specific molecular marker encodes a protein tyrosine kinase, BCR-ABL1, which is considered as the driver of the leukemic process. This discovery led to the developm...
متن کاملDeep molecular responses for treatment‐free remission in chronic myeloid leukemia
Several clinical trials have demonstrated that some patients with chronic myeloid leukemia in chronic phase (CML-CP) who achieve sustained deep molecular responses on tyrosine kinase inhibitor (TKI) therapy can safely suspend therapy and attempt treatment-free remission (TFR). Many TFR studies to date have enrolled imatinib-treated patients; however, the feasibility of TFR following nilotinib o...
متن کاملImmune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
Chronic myeloid leukemia (CML) is a hematological cancer, characterized by a reciprocal chromosomal translocation between chromosomes 9 and 22 [t(9;22)], producing the Bcr-Abl oncogene. Tyrosine kinase inhibitors (TKIs) represent the standard of care for CML patients and exert a dual mode of action: direct oncokinase inhibition and restoration of effector-mediated immune surveillance, which is ...
متن کاملTreatment-Free Remission by Tyrosine Kinase Inhibitor for Patients with Chronic Myeloid Leukemia
The prospective French cessation trial, Stop Imatinib trial (STIM) represents a breakthrough in Treatment-Free Remission (TFR) research in Chronic Myeloid Leukemia (CML) treatment with Tyrosine Kinase Inhibitors (TKIs). About 40% had long-term complete molecular response (CMR) after imatinib cessation in STIM trial. It demonstrated that imatinib cessation might be possible in monotherapy if CMR...
متن کاملTelomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients
We studied telomere length in 32 CML patients who discontinued imatinib after achieving complete molecular remission and 32 age-sex-matched controls. The relative telomere length (RTL) was determined by q-PCR as the telomere to single copy gene (36B4) ratio normalized to a reference sample (K-562 DNA). Age-corrected RTL (acRTL) was also obtained. The 36-month probability of treatment-free remis...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia & Lymphoma
سال: 2016
ISSN: 1042-8194,1029-2403
DOI: 10.1080/10428194.2016.1198959